Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of recombinant human TSH for postoperative radioactive iodine remnant ablation in differentiated thyroid cancer
CTR20211448Phase 3Completed
- Sponsor
- Zelgen
- Start
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of thyrotropin alfa in well-differentiated thyroid cancer (WDTC), sponsored by Zelgen. Started Oct 2021; status: completed.
02
Drugs
thyrotropin alfa
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on CTR20211448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211448.